The digital therapeutics company secured $8M capital infusion, led by Optum Ventures, the independent venture fund of Optum, part of UnitedHealth Group.
The partnership will help Kaia Health to accelerate sales growth in the U.S. healthcare market, extend its platform into other chronic indications and expand the supporting clinical evidence base.
Balderton previously led the firm's Series A in January 2019.